---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-010088"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:28:57.882390+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics Q4 rev $73.9M (+48%); FY rev $258.2M; raises FY24/25 guidance

## Summary
- Q4 2023 total revenue $73.9M, up 48% YoY; FY 2023 total revenue $258.2M, up 68% YoY.
- Q4 adjusted net income $8.5M (vs loss $12.2M); FY adjusted net income $0.7M (vs loss $59.2M).
- FY 2024 guidance raised: revenue >$330M, net income >$65M, adjusted EBITDA >$90M.
- FY 2025 guidance raised: revenue >$380M, net income >$115M, adjusted EBITDA >$140M.
- Pipeline: S. pneumonia hyperimmune globulin potential peak rev $300-500M; ASCENIV pediatric study ongoing.

## SEC filing metadata
- accession: 0001140361-24-010088
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036124010088/0001140361-24-010088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036124010088/ef20022668_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-010088
- JSON: https://secwatch.observer/filing/0001140361-24-010088.json
- Plain text: https://secwatch.observer/filing/0001140361-24-010088.txt

## Key facts
- Earnings Releases
  ADMA BIOLOGICS, INC. reported the full year 2023 and the three months ended December 31, 2023 results: revenue Total revenues were $73.9 million for the quarter ended December 31, 2023. Guidance raised.
  - Period: the full year 2023 and the three months ended December 31, 2023
  - Revenue: Total revenues were $73.9 million for the quarter ended December 31, 2023
  - Guidance: raised
  - Result: preliminary results
  source text: ADMA Biologics, Inc. issued a press release announcing its financial results for the full year 2023 and the three months ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036124010088/0001140361-24-010088-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.